We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Diagnostica Stago (Asnières-sur-Seine, France), which develops and markets automated systems for blood analysis, highlighted its Max Generation family of coagulation analyzers at MEDLAB Middle East 2021.

On display at the event was the STA R Max 3, a versatile analyzer that will adapt to any type of laboratory set-up, for an equivalent performance whether used alone or integrated into an automated track. More...
It is supported by a range of reagents offering a comprehensive menu of routine and specialized tests, ensuring effective TAT (turnaround time) management. Like its predecessor, the STA R Max 3 has an EPC module for checking sample integrity that controls fill volumes of all types of tubes and detects haemolysed, icteric and lipemic samples to ensure quality results. It requires no additional plasma volume and does not affect throughput.

The company also presented the STA Compact Max 3 which offers significant performance improvements and includes the EPC (expert pre-analytical check) module. This EPC module controls fill volumes of all types of tubes and detects haemolysed, icteric and lipemic samples, allowing the STA Compact Max 3 to check sample integrity to ensure quality results. It requires no additional plasma volume and does not affect throughput. In addition, the company highlighted the STA Satellite Max which builds on the proven strengths of the Max Generation, offering new functionalities and a user-friendly interface, making it the ideal solution for Haemostasis testing in low-volume labs. The STA Satellite Max is a Haemostasis analyzer designed specifically for “satellite” labs looking for a device that meets their needs while guaranteeing results as reliable as those obtained in large specialized laboratories.

At this year’s MEDLAB Middle East, the company showcased the STA R Max 3, a versatile analyzer that will adapt to any type of laboratory set-up, for an equivalent performance whether used alone or integrated into an automated track. It is supported by a range of reagents offering a comprehensive menu of routine and specialized tests, ensuring effective TAT (turnaround time) management.

Related Links:
Diagnostica Stago


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.